New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 5mg - film coated tablet - 5 mg - active: olanzapine 5mg excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 7.5mg - film coated tablet - 7.5 mg - active: olanzapine 7.5mg excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 10mg - orodispersible tablet - 10 mg - active: olanzapine 10mg excipient: carmellose calcium colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sucralose - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 15mg - orodispersible tablet - 15 mg - active: olanzapine 15mg excipient: carmellose calcium colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sucralose - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 20mg - orodispersible tablet - 20 mg - active: olanzapine 20mg excipient: carmellose calcium colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sucralose - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - olanzapine 5mg - orodispersible tablet - 5 mg - active: olanzapine 5mg excipient: carmellose calcium colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose sucralose - olanzapine is indicated for the treatment of schizophrenia and related psychoses.

Israel - English - Ministry of Health

abic marketing ltd, israel - olanzapine - film coated tablets - olanzapine 5 mg - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine teva® is indicated for the management of the manifestations of psychotic disorders. olanzapine teva® is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment olanzapine teva® is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder. the combination of olanzapine teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

European Union - English - EMA (European Medicines Agency)

apotex europe bv - olanzapine - schizophrenia; bipolar disorder - psycholeptics - olanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode.in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine tablets usp are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial [see clinical studies (14.1) ]. when deciding among the alternative treatments for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5, 5.6) ]. information describing the use of olanzapine tablets in pediatric patients with schizophrenia is approved for eli lilly and company’s olanzapine drug product labeling. however, due to eli lilly and company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. monotherapy olanzapine tablets usp are indicated for the acute

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)]. monotherapy — olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder.